Cipla Takes To Future Therapies With Stempeutics Pact; Says Preparing For The Big Changes In Research

MUMBAI - Future sciences like monoclonal antibodies or stem cell therapies are not just attracting the fancy of multinational companies scrambling to expand their pipelines; even generic drug makers like India's Cipla are getting drawn into start-up companies and demonstrating an ability to bring to market products that can potentially revolutionalize treatment regimens